GlassScriptPhysician profile
Sean M Mcfadden
NPI 1538101522
$18,690.92
in general payments reported to CMS, 2019-2025
20 companies · $1,325 in 2025
The $1,325 reported for 2025 was more than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,385 · 2020: $4,670 · 2021: $7,303 · 2022: $1,829 · 2023: $863 · 2024: $1,316 · 2025: $1,325.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,367 · Travel and Lodging: $138.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,366.64 |
| Travel and Lodging | $137.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Reel Surgical, INC. | $7,099.57 | 2020-2025 | |
| Stryker Corporation | $5,231.19 | 2019-2025 | Blueprint Patient Specific Instrumentation, Mako, Aequalis Perform |
| Regeneron Pharmaceuticals, INC. | $2,660.00 | 2020 | |
| Arthrex, INC. | $1,474.87 | 2019-2025 | |
| Wright Medical Technology, INC. | $789.61 | 2019 | |
| Avanos Medical | $317.03 | 2019-2021 | |
| Smith+Nephew, INC. | $316.63 | 2019-2025 | Q-Fix |
| Miach Orthopaedics, INC. | $177.96 | 2022 | |
| Revance Therapeutics, INC. | $155.39 | 2024 | Daxxify |
| Convatec INC. | $107.19 | 2019 | |
| Linvatec Corporation | $106.55 | 2024 | Biobrace 23mm |
| Ermi LLC | $100.08 | 2022 | |
| Pfizer INC. | $38.40 | 2020 | |
| Zyla Life Sciences, INC. | $28.70 | 2019 | |
| Ferring Pharmaceuticals INC. | $28.53 | 2024 | Euflexxa |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Heron Therapeutics, INC. | $22.88 | 2021 | |
| Pacira Therapeutics, INC. | $20.88 | 2021 | |
| Merck Sharp & Dohme LLC | $15.46 | 2023 | Bridion |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sean Mcfadden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.